Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0D8TE
|
|||
| Former ID |
DIB014537
|
|||
| Drug Name |
FBS-0701
|
|||
| Synonyms |
Desferrithiocin analog (oral, iron overload), FerroKin Biosciences; Iron chelator (oral, iron overload), FerroKin Biosciences
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Iron overload disease [ICD-11: 5C64.10; ICD-10: E83.1, G23.0] | Phase 2 | [1] | |
| Company |
FerroKin BioSciences Inc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H25NO7S
|
|||
| Canonical SMILES |
CC1(CSC(=N1)C2=C(C(=CC=C2)OCCOCCOCCOC)O)C(=O)O
|
|||
| InChI |
1S/C18H25NO7S/c1-18(17(21)22)12-27-16(19-18)13-4-3-5-14(15(13)20)26-11-10-25-9-8-24-7-6-23-2/h3-5,20H,6-12H2,1-2H3,(H,21,22)/t18-/m1/s1
|
|||
| InChIKey |
AWHIMFSHNAAMBM-GOSISDBHSA-N
|
|||
| CAS Number |
CAS 945635-15-4
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01186419) Safety and Pharmacodynamic Study of an Oral Iron Chelator Given for 6 Months to Patients With Iron Overload. U.S. National Institutes of Health. | |||
| REF 2 | A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma. Clin Cancer Res. 2009 Dec 1;15(23):7144-52. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.